ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 130 filers reported holding ASCENDIS PHARMA A/S in Q3 2019. The put-call ratio across all filers is 0.17 and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $1,200,864 | -28.6% | 11,200 | -38.1% | 0.00% | 0.0% |
Q2 2022 | $1,683,000 | -20.8% | 18,105 | 0.0% | 0.00% | 0.0% |
Q1 2022 | $2,125,000 | -70.3% | 18,105 | -65.8% | 0.00% | -60.0% |
Q4 2021 | $7,148,000 | +2.7% | 53,015 | +21.4% | 0.01% | 0.0% |
Q3 2021 | $6,959,000 | +213.0% | 43,660 | +158.4% | 0.01% | +150.0% |
Q2 2021 | $2,223,000 | -46.5% | 16,895 | -47.6% | 0.00% | -50.0% |
Q1 2021 | $4,153,000 | -27.8% | 32,225 | -6.5% | 0.00% | -33.3% |
Q4 2020 | $5,749,000 | +8.1% | 34,470 | 0.0% | 0.01% | 0.0% |
Q3 2020 | $5,319,000 | -7.2% | 34,470 | -11.0% | 0.01% | -14.3% |
Q2 2020 | $5,729,000 | +37.2% | 38,740 | +4.4% | 0.01% | +16.7% |
Q1 2020 | $4,177,000 | -22.0% | 37,095 | -3.6% | 0.01% | +20.0% |
Q4 2019 | $5,354,000 | +34.6% | 38,480 | -6.8% | 0.01% | +25.0% |
Q3 2019 | $3,977,000 | -36.5% | 41,305 | -24.0% | 0.00% | -33.3% |
Q2 2019 | $6,260,000 | -7.4% | 54,360 | -5.3% | 0.01% | -14.3% |
Q1 2019 | $6,759,000 | +151.0% | 57,430 | +31.1% | 0.01% | +133.3% |
Q4 2018 | $2,693,000 | -51.3% | 43,820 | -43.9% | 0.00% | -40.0% |
Q3 2018 | $5,535,000 | -43.6% | 78,120 | -47.0% | 0.01% | -50.0% |
Q2 2018 | $9,809,000 | -16.1% | 147,460 | -17.5% | 0.01% | -9.1% |
Q1 2018 | $11,689,000 | +63.6% | 178,720 | +0.2% | 0.01% | +83.3% |
Q4 2017 | $7,145,000 | +63.7% | 178,370 | +48.1% | 0.01% | +50.0% |
Q3 2017 | $4,366,000 | – | 120,450 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management III, LLC | 133,691 | $13,805,000 | 36.44% |
RA Capital Management | 7,567,900 | $781,462,000 | 16.67% |
Q Global Advisors, LLC | 145,209 | $16,699,000 | 11.49% |
BERYLSON CAPITAL PARTNERS, LLC | 51,000 | $5,266,000 | 8.70% |
Spyglass Capital Management LLC | 949,915 | $98,088,000 | 6.94% |
Paradigm Biocapital Advisors LP | 497,347 | $51,356,000 | 6.85% |
Avoro Capital Advisors LLC | 2,850,000 | $294,291,000 | 5.44% |
Deep Track Capital, LP | 1,000,000 | $103,260,000 | 4.73% |
Finepoint Capital LP | 123,400 | $12,742,000 | 4.19% |
Deep Track Capital, LP | 800,000 | $82,608,000 | 3.78% |